Apotex Releases New Supply of Tamoxifen into Canadian Market
Dec 5, 2019Expedited Release Occurs Earlier Than Anticipated
December 5th, 2019, Toronto, Ontario - Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
Collaborating with Health Canada, Apotex expedited the return to market almost one month earlier than their latest projection.
“Our goal from the outset was to make the Canadian supply available as soon as possible to reduce the impact on patients,” said Jeff Watson, President & CEO, Apotex Inc. “We recognize the importance of this medication and that it can be unsettling for patients if it is in short supply. To facilitate a quicker re-entry to the market, we re-prioritized production of our portfolio, and were able to produce this faster than we normally would,” said Watson.
Indeed, Apotex had initially projected a release by the end of January and was then able to advance that deadline to December 31st, 2019. With additional pressure on the manufacturing teams, they were able to accelerate this date to an even earlier time.
“There’s no doubt that being a Canadian-based manufacturer and having a flexible supply chain were key enablers in us achieving this goal,” said Mr. Watson.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.